Please assess the completion status of the following clinical trial:

Trial Title: Collection of Blood Samples in Patients With Non-small Cell Lung Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* A diagnosis of non-small cell lung carcinoma for which the molecular profile of the primary tumor has been obtained from a block of paraffin-embedded, formalin-fixed tissue that remains available~* Zubrod performance status 0 or 1~* Patients must have metastatic or unresectable disease and be starting a new line of systemic treatment at the time of enrollment; there are no constraints regarding the time interval between the initial collection of samples for molecular profiling studies at the time of diagnosis prior to treatment and subsequent collections of circulating cell-free deoxyribonucleic acid (DNA) or circulating tumor cells~* Patients must have measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1~* Ability to understand and the willingness to sign a written informed consent; Note: There will be no discrimination between type of treatment or whether they are on continuous versus intermittent therapy~Exclusion Criteria:~* Known severe anemia (hemoglobin \[Hb\] \< 8g/dL)~* Patients will be excluded if trackable driver mutations are not identified in the primary tumor tissue

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ancillary-Correlative (biospecimen collection) (Type: None): Patients undergo collection of blood samples at baseline and every 12 weeks for up to 6 times.

Based on this trial design, predict the completion outcome and termination type (if applicable).